中文

三元生物 Revenue Breakdown

Period 2026-03-31 ・ Reported 2026-04-29
ItemAmountY/Y
Revenue¥0.22B+49.6%
Gross profit¥0.04B
Operating income¥0.03B
Net income¥0.03B+4.8%
Gross margin16.7%Net margin 11.6%
Revenue Q/Q+29.6%

Revenue Segments

The filing did not disclose a revenue breakdown for this period.

Costs & Expenses

ItemAmount% of revenue
Cost of revenue¥0.19B83.3%
R&D¥0.01B3.7%
SG&A¥0.01B4.5%
Tax & other¥0.00B1.5%
Generate the full Sankey chart →

The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.

Other companies

华兰疫苗中亦科技联合化学金杨精密亨迪药业联盛化学观想科技中汽股份万凯新材铜冠铜箔华是科技腾远钴业

Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies